

Madrid, April 1, 2026

LABIANA HEALTH, S.A. (hereinafter, the “Company”), in compliance with the provisions of Article 17 of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of April 16, 2014, on market abuse, and in accordance with the provisions of Article 227 of Law 6/2023 of March 17 on Securities Markets and Investment Services, as well as Circular 3/2020 of the BME Growth segment of BME MTF Equity, regarding information to be provided by companies listed for trading on said segment, hereby announces the following:

OTHER RELEVANT INFORMATION

Further to the “material information” disclosure dated March 19, 2026, regarding the outcome of the Company’s capital increase, we hereby announce that, on March 27, 2026, the Company proceeded with the sale of 127,747 treasury shares from its treasury stock at a price of 4.00 euros per share, matching the issue price of the aforementioned capital increase, which amounted to a total of 510,988 euros.

This transaction was conducted over-the-counter (OTC) with the aim of meeting the high demand received from investors following the oversubscription of the aforementioned capital increase and in order to enhance the Company’s liquidity and free float in the market.

It is expressly stated that the shares subject to this notice come from the **Company’s treasury stock** and that this transaction **is not linked to nor part of any share repurchase program**.

In compliance with the provisions of Circular 3/2020 of BME MTF Equity, it is hereby expressly stated that the information disclosed herein has been prepared under the sole responsibility of the Company and its directors.

We remain at your disposal for any further clarification you may require.

Sincerely,

Mr. Manuel Ramos Ortega
Chief Executive Officer
LABIANA HEALTH, S.A.